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ABSTRACT
Alpha-synuclein (α-SYN) is the main component of anomalous protein aggregates 
(Lewy bodies) that play a crucial role in several neurodegenerative diseases 
(synucleinopathies) like Parkinson’s disease and multiple system atrophy. However, 
the mechanisms involved in its transcriptional regulation are poorly understood. 
We investigated here the role of the cyclin-dependent kinase (Cdk) inhibitor and 
transcriptional regulator p27Kip1 (p27) in the regulation of α-SYN expression. We 
observed that selective deletion of p27 by CRISPR/Cas9 technology in neural cells 
resulted in increased levels of α-SYN. Knock-down of the member of the same 
family p21Cip1 (p21) also led to increased α-SYN levels, indicating that p27 and p21 
collaborate in the repression of α-SYN transcription. We demonstrated that this 
repression is mediated by the transcription factor E2F4 and the member of the 
retinoblastoma protein family p130 and that it is dependent of Cdk activity. Chromatin 
immunoprecipitation analysis revealed specific binding sites for p27, p21 and E2F4 in 
the proximal α-SYN gene promoter. Finally, luciferase assays revealed a direct action 
of p27, p21 and E2F4 in α-SYN gene expression. Our findings reveal for the first time 
a negative regulatory mechanism of α-SYN expression, suggesting a putative role for 
cell cycle regulators in the etiology of synucleinopathies.
INTRODUCTION
p27Kip1 (p27) encoded by the CDKN1B 
gene belongs to the Cip/Kip family of inhibitors 
of cyclin dependent kinases (Cdks) [1]. Cdks are a 
family of kinases involved in the regulation of the 
cell division cycle whose activity is regulated by a 
number of mechanisms that include cyclin association, 
phosphorylation, acetylation and binding to inhibitory 
proteins [2–5]. In addition to p27, the Cip/Kip family 
of Cdk inhibitors includes p21(Cip1) and p57(Kip2). 
Classically, the role of p27 was to inhibit the activity 
of cyclin- Cdk complexes by associating with both 
the cyclin and the Cdk. This association is performed 
by specific regions located at the NH2 terminus of 
the protein. The inhibitory effect is caused by the 
introduction of a specific small region of p27 inside 
of the catalytic cleave of the Cdk [2]. However, recent 
work has described that specific phosphorylations in 
tyrosine residues of p27 located in a domain, close to 
that interacting with the catalytic center of the Cdk, 
induce conformational changes in p27 leading to a 
decrease in its Cdk inhibitory capacity. Specifically, 
phosphorylations in Y74, Y88 and Y89 of p27 by 
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different tyrosine kinases, mostly of the Src family, 
reduce the inhibition of Cdk activity by p27, despite p27 
remains associated with the complex [6–8]. Thus, now, 
the concept is that p27 is not strictly a Cdk inhibitor 
but it is a Cdk regulator that when associated with 
cyclin-Cdk complexes might or not inhibit Cdk activity 
on depending on its phosphorylation status. This is 
compatible with previous reports showing Cdk4 activity 
in ternary p27-cyclin D3-Cdk4 complexes [9]. p27 has a 
relatively long carboxyl-moiety that has been identified 
as an intrinsically disordered region [10]. It means that 
it can adopt multiple conformations that confer to this 
region the capacity to interact with a significant number 
of different protein partners.
In addition to its role as a regulator of cyclin-Cdk 
activity, recent works have identified a new function 
of p27 as a transcriptional regulator [11]. Since it is 
not able to directly interact with DNA, its capability 
to behave as a transcriptional regulator is mediated by 
the association with a number of regulatory proteins 
as transcription factors (TFs), co-activators or co-
repressors. Several reports by our group have revealed 
that p27 mostly interacts with distant intergenic and 
intronic regions of the chromatin although it can also 
associate with specific gene promoters [11–13]. p27 
has been shown to interact with TFs as E2F4, Ets-1 and 
PAX5 and with the transcriptional co-activator (with 
acetyltransferase activity) PCAF [11, 13, 14]. Our group 
has been intensively working in the mechanisms of how 
p27 regulates the expression of E2F4 repressed genes. 
E2F4 participates in transcriptional repressor complexes 
that include p130 (a member of the retinoblastoma 
family) and other transcriptional co-repressors as 
several HDAC (histone deacetylases) and mSIN3A 
[11]. These complexes are specifically relevant because 
they associate to promoters of genes needed for DNA 
replication during the G1 phase of the cell cycle and 
repress their expression. p27 is able to directly associate 
with E2F4 and p130 by its carboxyl-terminal domain 
and in such a way it participates in the repressor 
function of these complexes [11]. Interestingly, during 
early and mid G1 phase of the cell cycle p27, associated 
with p130/E2F4 on the promoters, recruits cyclin D2/
D3-Cdk4 complexes by its NH2 domain. Since p130 
is a substrate of Cdk4, the role of p27 is to bring near 
p130 the kinase Cdk4 that after its subsequent activation 
will phosphorylate p130. At late G1, p27-cyclin D2/3 
and Cdk4 are released from the p130/E2F4 complexes 
and are substituted by p21-cyclin D1-Cdk2 that by 
phosphorylating p130 remove these repressor complexes 
from the gene promoters allowing transcription of these 
genes [15]. Thus, in such a way, p27 and p21 collaborate 
in the transcriptional regulation of genes repressed by 
p130/E2F4 complexes. Expression of important genes, 
as for instance SOX2 involved in pluripotency, are also 
regulated by this mechanism [16, 17]. Recent reports 
also revealed that p27 collaborates with PAX5 and the 
transcriptional co-activator PCAF in the regulation 
of a number of genes involved in different cellular 
functions [14].
Expression microarray analysis performed 
in different cellular types have allowed the 
identification  of the transcriptional programs regulated 
by p27 [11, 13, 18]. Interestingly, in addition to the 
expected involvement of p27 in the regulation of 
cell cycle, it also participates in the regulation of the 
expression of genes involved in transcription, splicing 
and respiration, among others [11]. Since low levels 
of p27 in tumors have been associated with a worse 
outcome of patients [19–21], it has been postulated 
that deregulation of these transcriptional programs 
in low-p27 tumors play an important role in their 
progression to malignancy [11].
Surprisingly, expression microarray analysis 
performed in mice embryonic fibroblasts (MEFs) 
from p27 knock out (p27KO) animals versus control 
revealed that a significant number of genes involved 
in Parkinson’s disease (PD) were significantly 
deregulated [18]. These genes are involved in the 
induction of the three main Hallmarks of PD: Lewy 
pathology (accumulation and α-synuclein (α-SYN) 
aggregates), mitochondrial dysfunction and neuro-
inflammation. It merits to emphasize that in p27KO-
MEFs α-SYN mRNA is increased more than 8 fold. 
Since a neuropathological hallmark of PD and other 
α-synucleinopathies is the intracellular accumulation of 
misfolded α-SYN we aimed to analyze the putative role 
of p27 in the regulation of α-SYN expression. Despite 
the intense debate of how α-SYN pathology initiates 
and spreads in the nervous system, the mechanisms 
involved in the regulation of α-SYN expression still 
remain largely unknown. We report here that α-SYN 
transcription is regulated by p27 in collaboration with 
p21, mediated by p130/E2F4 complexes and depending 
of Cdk activity. These results suggest a putative 
involvement of p27 in the etiology of PD and perhaps 
other α-synucleinopathies.
RESULTS
p27 and p21 regulate the expression of α-SYN in 
c17.2 neural stem cells
Previous expression microarray analyses 
revealed an 8-fold increase of α-SYN mRNA in p27KO 
MEFs, suggesting that p27 might be involved in the 
transcriptional regulation of this gene [18]. To study this 
possibility, we generated a p27 deletion in c17.2 neural 
stem cells [22] using the CRISPR/Cas9 methodology. 
Next we selected different clones in which p27 was 
effectively deleted. Because we had reported that in 
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MEFs, p27 regulates the expression of p21 [18] and, 
as aforementioned, p21 can collaborate with p27 in the 
regulation of different p130/E2F4 repressed genes [15], 
we first checked whether in c17.2 wt clones there was 
a correlation between p27 and p21 protein levels. As 
expected, we observed an inverse correlation of p27 and 
p21 in these clones. It can be seen that the clones with 
higher levels of p27 display lower amounts of p21 and 
vice versa. (Figure 1A and 1B).
We then quantified the levels of α-SYN in the 
p27-null cells. WB analysis revealed that elimination of 
p27 resulted in increased amount of α-SYN (Figure 1C). 
Accordingly, we could also detect elevated levels of 
α-SYN mRNA in these cells (Figure 1D). To evaluate 
whether this was specifically mediated by p27, we re-
introduced a wt version of p27 in p27-CRISPered cells. 
Overexpression of p27 in these cells rescued the phenotype 
and decreased both the α-SYN protein (Figure 1E) and 
mRNA levels (Figure 1F). On the other hand, to examine 
the possibility of an additional role of p21 in the regulation 
of α-SYN expression we knocked down (KD) p21 in a 
control clone with specific shRNAs. As observed in 
Figure 2A, decreasing p21 induces the elevation of α-SYN. 
Finally, we introduced the p21 shRNA into a p27KO clone 
and evaluated the effect on α-SYN expression finding that 
both α-SYN protein (Figure 2B) and mRNA (Figure 2C) 
were further increased. Together, all these results suggest 
that p27, in collaboration with p21, regulates α-SYN 
expression.
As p27 and p21 are classical inhibitors of different 
cyclin-Cdk complexes, the absence of these proteins 
induces the increase of Cdk activity that, according to 
our model of transcriptional regulation, will induce the 
expression of target genes by phosphorylating specific 
transcriptional regulators, as for instance p130. Thus, 
we aimed to analyze here the effect of the Cdk inhibitor 
Roscovitine on α-SYN expression in c17.2 cells. As it 
can be seen in Figure 2D, Roscovitine reduces the α-SYN 
levels in the cells, indicating that cyclin-Cdk complexes 
participate in the regulation of α-SYN expression.
p27 regulation of α-SYN expression is mediated 
by p130/E2F4 complexes
As p27 and p21 collaborate in the transcriptional 
regulation of p130/E2F4 repressed genes [15], we aimed 
to analyze the possibility that p27 and p21 regulate 
α-SYN expression trough the participation of p130/
E2F4 complexes. Thus, we first determined the levels of 
α-SYN in E2F4KO MEFs finding elevated α-SYN protein 
(Figure 3A) and mRNA (Figure 3B) in the absence of 
E2F4. The increase in α-SYN protein was also observed 
when E2F4 was knocked down in a different cellular type, 
as 293T (Supplementary Figure 1). Since E2F4 loading 
on its target promoters requires the presence of p130, we 
also analyzed the α-SYN levels in p130KO MEFs. As 
shown in Figure 3C, we observed an increase in α-SYN 
expression in these cells. Additionally, we found that 
α-SYN increased in double KO (p130 and p27) MEFs 
(Figure 3D).
p27, p21 and E2F4 associate with specific regions 
of the Snca gene promoter and regulate its 
transcription
To analyze whether p27 directly regulates α-SYN 
expression, we first identified, by in silico analysis 
(bioinformatics tools from FIMO web site), specific 
E2F4 consensus sequences on the α-SYN promoter. As 
observed in Figure 4A, two regions (region 1 (from -2200 
to – 1350 bp) and region 2 (from -300 bp to TSS)) on 
the proximal α-SYN promoter contain putative E2F4 
consensus sequences. Sequence *1 was located in region 
1 whereas sequences *2 and *3 were located in region 
2. We designed specific primers to detect these regions 
after ChIP analysis (Supplementary Table 1). ChIP was 
performed in c17.2 cells using specific anti-E2F4, anti-p27 
and anti-p21 antibodies. ChIP with no antibodies was used 
as a control. The specific association of E2F4, p27 and 
p21 to regions 1 and 2 was detected by qPCR using the 
designed primers. We observed that E2F4 significantly 
associates with region 1 (Figure 4B) and region 2 (Figure 
4C). Interestingly, both p27 and p21 can be also found to 
associate with the same regions of the α-SYN promoter 
(Figure 4B and 4C). These results clearly indicate that 
p27 and p21 can associate to these regions through its 
interaction with E2F4, as previously shown in other gene 
promoters [11, 15].
Finally, we also performed luciferase assays as 
a functional demonstration of the interaction of p27, 
p21 and E2F4 with the α-SYN promoter. To do so, 
we transfected 293T cells with a vector containing a 
luciferase reporter gene under the control of the α-SYN 
promoter. Additionally, we knocked down p27, p21 or 
E2F4 using specific shRNAs and subsequently quantified 
luciferase expression. Results indicated that elimination 
of p27 (Figure 4D), p21 (Figure 4E) or E2F4 (Figure 
4F) significantly induced the expression of the α-SYN 
–driven luciferase reporter. These results confirm that 
α-SYN transcription is actively repressed by p27/p21/
E2F4 complexes, revealing a specific role of p27 (with 
the collaboration of p21) in the regulation of α-SYN 
expression.
Increased levels of α-SYN in cerebellar cells of 
p27 KO mice
In light of our molecular data, we next decided to 
evaluate whether we could observe any inverse correlation 
between p27 and α-SYN levels in the adult brain. We 
selected the cerebellum because it has been described 
that Purkinje and granule cells have detectable levels 
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Figure 1: p27 regulates α-SYN expression. (A) c17.2 cells were knocked out for p27 by using the CRISPR/Cas9 methodology. 
Then, severalcontrol c17.2 clones were assessed for p27 and p21 by WB. Tubulin was used as a loading control. (B) The bands from Figure 
1A were quantified by using the image J program. After normalizing data respect tubulin, a correlation between p27 and p21 levels was 
analyzed using the regression lineal program SPSS. The significance was P<0.05. The value of the Pearson correlation was -0,762. (C) The 
levels of p27 and α-SYN were determined by WB in two control clones (1 and 2) and two p27KO clones (P1 and P2). Tubulin was used as 
a loading control. (D) Levels of α-SYN mRNA were determined in the same samples by qPCR. Results are expressed relative to Control 
1 (Ctrl1). (E) Cells from the p27KO clone P1 were infected with lentiviruses with an empty vector (Ф) or with wild-type p27 (p27wt). 
Then, protein levels of p27 and α-SYN protein were determined by WB. Tubulin was used as a loading control. (F) α-SYN mRNA levels 
were determined by qPCR in the same cells as in (E). In all experiments results are the mean value ± SD of at least three independent 
experiments. Statistical analyses were performed using the Student’s t-test. ***P<0.001.
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of p27 [23]. Accordingly, immunohistochemistry with 
specific p27 antibodies performed on WT murine adult 
cerebellar tissue showed that most of the neurons in the 
granule cell layer contain high amounts of nuclear p27 
(Figure 5A and Supplementary Figure 2A). We confirmed 
the specificity of the staining using p27-KO tissue as a 
control (Figure 5B and Supplementary Figure 2A). Since 
p27 and p21 collaborate in the transcriptional regulation 
of several genes [15] and it has been shown in MEFs 
that p21 expression might be repressed by p27 [18], we 
also performed immunohistochemistry using anti-p21 
antibodies in cerebellar sections from WT and p27KO 
mice. In the absence of p27, p21 levels were increased 
in Purkinje neurons but interestingly not in granule cells 
(Figure 5E, 5F and Supplementary Figure 3). These results 
indicate that, rather than being a general phenomenon, the 
induction of p21 in cells lacking p27, seems to be cell 
type-specific.
In this scenario, we analyzed the levels of α-SYN in 
the granule cell layer in both WT and p27-null tissue. Our 
results reveal that, contrary to the pattern found on WT 
tissue (Figure 5C), increased levels of α-SYN aggregates 
can be clearly detected in cells from the p27KO sections 
(Figure 5D). It can also be observed that these aggregates 
are located in non-nuclear domains (Figure 5D). The 
specificity of the α-SYN antibodies was confirmed using 
cerebellar sections of α-SYN KO animals (Supplementary 
Figure 2B). These results support a potential role of p27 
and p21 in the regulation of α-SYN expression.
DISCUSSION
Our results identify p27 as a transcriptional regulator 
of α-SYN expression. The data add to previous results 
demonstrating a role for p27 in gene expression aside its 
canonical role as Cdk-inhibitor. Furthermore, our finding 
that α-SYN expression is under the control of p27, also 
in vivo, suggest an intriguing novel connection between 
p27 and PD that may reveal p27 as a potential therapeutic 
target.
Synucleinopathies are neurodegenerative diseases 
characterized by the abnormal accumulation of aggregates 
of α-SYN protein in neurons, nerve fibers or glial cells [24].
There are three main types of synucleinopathy: 
Parkinson's disease (PD), dementia with Lewy bodies, 
and multiple system atrophy. Other rare disorders, such 
as various neuroaxonal dystrophies, also have α-synuclein 
pathologies.
PD is a common neurodegenerative disorder that 
affects 2–3% of the population ≥65 years of age [25]. 
The characteristic features of PD include neuronal loss 
in the substantia nigra pars compacta which causes 
Figure 2: p21 regulates α-SYN expression. (A) Levels of α-SYN and p21 were determined in c17.2 control cells infected with 
ShRNA control or ShRNA for p21. Tubulin was used as a loading control. (B) Cells from the p27KO clone P1 were infected with ShRNA 
control or ShRNA for p21 and subsequently assessed for p27, p21 and α-SYN protein by WB. Tubulin was used as a loading control. 
(C) α-SYN mRNA levels were determined by qPCR in the same cells as in (B). (D) α-SYN protein levels were determined in c17.2 cells 
treated or not with the Cdk inhibitor Roscovitine (20 μM). In all experiments results are the mean value ± SD of at least three independent 
experiments. Statistical analyses were performed using the Student’s t-test. ***P<0.001.
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striatal dopamine deficiency and intracellular inclusions 
containing aggregates of α-SYN. In PD patients, these 
α-SYN inclusions (Lewy bodies) are found in certain 
neurons of different regions of the brain [26, 27]. In 
heritable forms of this disease, mutations in the α-SYN 
gene (SNCA) have been observed and this observation 
supports the important role of this protein in PD [28, 29].
The functional roles of α-SYN are not well 
characterized but it is mainly located in the presynaptic 
terminals of neurons, although it can be nuclear or it 
may be also in the mitochondria. It has been involved in 
synaptic vesicle dynamics, mitochondrial function and in 
intracellular trafficking [29]. α-SYN acquires neurotoxic 
properties since the soluble monomers can form oligomers 
and subsequently large fibrils that finally aggregate to 
make up the Lewy bodies [30, 31]. The determinants 
of this aggregation can be multiple: overproduction of 
the protein, the presence of mutations or impairment 
of the mechanisms involved in its degradation [25]. 
As mutations of SNCA are observed only in a reduced 
number of PD patients [32], in most of the non-heritable 
forms of PD (sporadic PD) the accumulation of α-SYN 
by overproduction or by impairment of the degradative 
mechanisms are the most significant causes of the 
generation of Lewy bodies.
Despite the relevance of α-SYN in PD very few is 
known about the mechanisms involved in the regulation 
of its expression. There only few reports focused in the 
regulation of α-SYN transcription. Specifically, it has been 
shown that four TFs, namely C/EBPβ, GATA-1/2, ZSCAN 
21 and ZNF 219 can associate with regions of the intron 
1 of SNCA gene thus activating its expression [33–36]. 
Figure 3: E2F4 and p130 regulate α-SYN expression. (A) Control MEFS and E2F4 KO MEFs were assessed for E2F4 and α-SYN 
by WB. Tubulin was used as a loading control. (B) α-SYN mRNA levels were determined by qPCR in the same cells as in (A). Results are 
expressed relative to Control 1 (Ctrl1). (C) Control MEFS (WT) and p130 KO MEFs were assessed for p130 and α-SYN by WB. Tubulin 
was used as a loading control. (D) Control MEFS (WT) and double KO MEFs p130/p27 (DKO) were assessed for p130, p27 and α-SYN by 
WB. Tubulin was used as a loading control. In all experiments results are the mean value ± SD of at least three independent experiments. 
Statistical analyses were performed using the Student’s t-test. **P<0.01 and ***P<0.001.
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Figure 4: ChIP and luciferase assays. (A) Representation of the putative E2F4 binding sites in the SNCA promoter. Two regions 
(region 1 (from -2200 to -1350 bp) and region 2 (from -300 bp to TSS)) on the proximal α-SYN promoter contain putative E2F4 consensus 
sequences. Sequence *1 was located in region 1 whereas sequences *2 and *3 were located in region 2. (B) E2F4, p21 and p27 association 
with Region 1 of the SNCA promoter as determined by ChIP in c17.2 cells. (C) E2F4, p21 and p27 association with Region 2 of the SNCA 
promoter as determined by ChIP in c17.2 cells. (D) Expression of luciferase reporter gene in 293T cells infected with ShRNA control or 
ShRNA for p27. A WB showing the levels of p27 is shown in the bottom panel. (E) Expression of luciferase reporter gene in 293T cells 
infected with ShRNA control or ShRNA for p21. A WB showing the levels of p21 is shown in the bottom panel. (F) Expression of luciferase 
reporter gene in 293T cells infected with ShRNA control or ShRNA for E2F4. A WB showing the levels of E2F4 is shown in the bottom 
panel. In all experiments results are the mean value ± SD of at least three independent experiments. Statistical analyses were performed 
using the Student’s t-test. *P<0.05, **P<0.01 and ***P<0.001.
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More recently, it has been shown that the association 
of p53 to the SNCA promoter induces the expression 
of α-SYN [37]. Despite of this promising advances, the 
putative role of α-SYN transcriptional regulation by 
these TFs in PD induction and propagation still remains 
to be clarified. Our findings describe for the first time a 
mechanism of repression of SNCA. Specifically, we report 
here that neural c17.2 - p27KO cells expressed higher 
levels of α-SYN mRNA than controls, suggesting that p27 
might be involved in negative transcriptional regulation 
of α-SYN. We confirmed that the observed increase of 
α-SYN, in these p27KO cells, depends on p27 by showing 
that the re-introduction of p27 in these cells induces a 
decrease of α-SYN. We further supported this evidence 
by demonstrating the association of p27 with two specific 
regions of the SCNA gene promoter and by luciferase 
assays in which luciferase expression is under the control 
the α-SYN promoter. These luciferase experiments 
demonstrated that the decrease of p27 induced α-SYN 
expression. Finally, further support was provided by the 
observation that α-SYN accumulates in the granular cell 
layer of the cerebellum from p27KO mice. The origin of 
this α-SYN is still unknown.
We next explored whether p21 collaborates with 
p27 in the transcriptional regulation of α-SYN expression. 
We previously reported that p27 indirectly regulates p21 
expression in MEFs. Specifically, we demonstrated that 
p27 represses the expression of Pitx2, a transcriptional 
activator of p21. However, our observation that in 
cerebellar sections of p27KO mice p21 only increases 
in Purkinje cells but, on the contrary, it decreases in the 
granule cell layer, indicates that this p21 regulation by 
p27 is cell-type depending but not a general phenomenon. 
We describe here that knocking down p21 induces the 
Figure 5: p27, p21 and α-SYN levels in cerebellar sections from WT and p27KO mice. Distribution of p27, p21 and α-SYN 
was visualized by immunohistochemistry in cerebellum sections from WT and p27KO mice. (A) p27 stained sections from WT animals. 
Nuclear staining of p27 can be observed in the granule cell layer (GCL). (B) p27 stained sections from p27KO mice. (C) α-SYN staining 
in sections from WT mice. (D) α-SYN staining in sections from p27KO mice. (E) p21 stained sections from WT animals. (F) p21 stained 
sections from p27KO animals. Arrows indicate Purkinje cells. Scale bar = 10 μm.
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increase of α-SYN expression not only in control cells 
but also in p27KO clones. These collaboration between 
p27 and p21 in the regulation of α-SYN expression 
strongly supported that this gene could be repressed by 
p130/E2F4 complexes. We confirmed this possibility by 
demonstrating that in both E2F4- or p130-KO cells a clear 
increase of α-SYN levels was induced.
Interestingly, ChIP analysis revealed that p21 and 
E2F4 also associate with the same two specific regions 
of the α-Syn promoter that also interact with p27. Finally, 
luciferase assay confirms that p21 and E2F4 also directly 
regulate α-SYN transcription.
Thus, our results describe the mechanism by which 
p27 in collaboration with p21 regulates the expression of 
α-SYN through the interaction with p130/E2F4 repressor 
complexes as it has been reported for cell cycle genes 
but also for other no cell cycle related genes as Sox2. 
Interestingly, this regulatory mechanism also involves 
different cyclin-Cdk complexes that would phosphorylate 
p130 [15]. We report here that Cdk inhibition by 
Roscovitine induced a decrease of α-SYN expression 
indicating a role of Cdks in this regulation. All these 
results reveal that p27 in collaboration with p21 regulates 
α-SYN expression by a mechanism involving p130/E2F4 
repressive complexes and cyclin-Cdks, according to a 
model previously reported by our group [15].
The description of this mechanism is especially 
relevant in the context of synucleinopathies and opens the 
possibility of a participation of p27 in the induction and 
propagation of these diseases. Specifically, it should be of 
interest to analyze whether in the sporadic forms of PD or 
in the cerebellar subtype of the multiple system atrophy, 
formation of α-SYN aggregates could be a consequence of 
a progressive decrease of p27 levels in the affected cells. 
This possibility is compatible with results reported here 
indicating that the decrease of p27 induce an elevated 
expression of α-SYN.
In summary, we describe here for the first time 
a mechanism involved in the negative regulation of 
α-SYN expression. This regulation is performed by p27 
in collaboration with p21 and mediated by p130/E2F4 
repressor complexes. These results allows to postulate 
that this regulatory mechanism can be disrupted or altered 
in the process of induction or/and propagation of PD and 
other synucleinopathies. Thus, α-SYN accumulation, 
aggregation and toxicity in patients affected of any 
synucleinopathy could putatively be associated with a 
progressive alteration of this regulatory mechanism.
MATERIALS AND METHODS
Cell culture and transfection
HEK-293T cells (from ATCC), c17.2 cells (a 
kind gift of Dr. Evan Snyder), p130KO and double 
p130/p27 KO MEFs- (a kind gift from Dr Anxo Vidal), 
p27KO, p21 KO and E2F4 KO MEFs were cultured in 
Dulbecco’s modified Eagle Medium supplemented with 
10% fetal bovine serum, 5% Glutamine and 5% Penicillin/
Streptomycin. Cultures were maintained at 37°C and 5% 
CO2. Plasmids were transfected in HEK-293T cells using 
lipofectamine 2000 (Invitrogen) following manufacturer’s 
instructions. The Cdk inhibitor Roscovitine (Sigma) was 
added to the culture at 20 μM final concentration. All cells 
were free from mycoplasma.
Animals
All animal experiments were performed in 
accordance with the Guidelines of the European Union 
Council (86/609/EU) and Spanish Government (BOE 
67/8509-12) and approved by the Ethics and Scientific 
Committees of the Spanish National Research Council 
(CSIC) and the University of Barcelona. All the protocols 
used were registered at the “Departament d’Agricultura, 
Ramaderia, Pesca, Alimentació i Medi Natural de la 
Generalitat de Catalunya”. Mice were maintained 
under regulated light and temperature conditions at the 
animal facilities of the Faculty of Medicine, University 
of Barcelona. All efforts were made to minimize animal 
suffering and discomfort and to reduce the number of 
animals used. Under deep anesthesia with pentobarbital, 
adult mice were intracardially perfused with phosphate-
buffered saline (PBS) followed by 4% paraformaldehyde 
in 0.1 M phosphate buffer (PB).The brains were removed 
and post-fixed in the same solution overnight at 4°C. After 
several washes with PB, samples were processed and 
dehydrated through a series of graded ethanol to xylene 
and infiltrated with paraffin. Serially sectioned sagittal 
sections (5 μm) were obtained using a Microtome. The 
sections were mounted on gelatin-coated slides.
Immunohistochemistry
After dewaxing with xylene and rehydrated with 
graded ethanols, sections were pretreated in an autoclave 
for 15 min at 120°C in antigen retrieval reagent-basic 
(R&D, CTS013). Following incubation, samples were 
cooled to room temperature (approximately 5-10 min). 
After one wash in PBS, sections were permeabilized 
with three washes (5 min each) of 0.3% Triton X-100 
in PBS (PBST). Then, they were treated with H2O2 
(3%)-methanol to inhibit endogenous peroxidases and 
subsequently incubated with 10% normal serum in PBST 
during 2 h to prevent non-specific binding. Finally, 
sections were incubated overnight at 4°C with primary 
antibodies: mouse monoclonal anti-p27 (1/50; BD 
Biosciences, 610242); mouse monoclonal anti-p21 (1/50, 
Santa Cruz, Sc-6246) and rabbit polyclonal anti-α-SYN 
(1/250, Santa Cruz, Sc-7011). After washing, sections 
were reacted with biotinylated-conjugated secondary 
antibodies (1/200 Vector, biotinylated anti-mouse, Cat. 
BA-2000 or biotinylated anti-rabbit, BA-1000) using an 
ABC peroxidase staining kit (Thermo Scientific, 32020). 
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Diaminobenzidine was used as the chromogen. Sections 
were counterstained with hematoxylin. After one wash 
with PBS, they were dehydrated in graded alcohol to 
xylene and mounted with DePeX. Negative controls: the 
specificity of p27 and α-SYN primary antibodies was 
verified using the appropriate KO mice. The specificity 
of p21 primary antibody was verified in a previous work 
[38]. Microscopy images were obtained with an Eclipse 
1000 Nikon microscope (Nikon, Tokyo, Japan) and a 
digital camera (Olympus DP72, Tokyo, Japan).
Gel electrophoresis and Western blotting
Samples were loaded on sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) gels. 
After electrophoresis, gels were transferred to Hybond-C 
(Amersham Life Sciences) membranes. Then, transferred 
proteins were subjected to western blotting (WB) using the 
following antibodies: anti-p21 (sc-6246) and anti-E2F4 
(sc-866) from Santa Cruz, anti-p27 (610242) from BD 
Transduction Laboratories, anti- α-SYN (610787) from 
BD Biosciences and anti-tubulin (T9026) from Sigma 
Aldrich.
Chromatin immunoprecipitation
c17.2 cells were grown in an 80% confluence 
plate. Chromatin immunoprecipitation (ChIP) assays 
were performed as previously described [39]. Briefly, 
cells were lysed and chromatin from crosslinked cells 
was sonicated. Chromatin was incubated with 5 μg of 
anti-p27 (C-19, Santa Cruz), anti-p21 (sc-397, Santa 
Cruz) or anti-E2F4 (sc-866, Santa Cruz) in RIPA buffer 
(50 mM Tris - HCl pH 7.5, 150 mM NaCl, 1% NP-40, 
0.5% Sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 
1 mM DTT, 1 mM PMSF, 0.1 mM Na3VO4, 0.5 μg/μl 
aprotinin, 10 μg/μl leupeptin) adding 20 μl of Magna 
ChIP Protein A magnetic beads (Millipore). Samples were 
incubated in rotation overnight at 4°C. Samples incubated 
without antibodies were used as a control. Beads were 
washed with low-salt buffer, high-salt buffer, LiCl buffer 
and TE buffer. Subsequent elution and purification of 
the immunoprecipitated DNA-protein complexes was 
performed using the IPure kit (Diagenode) according to 
manufacturer’s protocol. Samples were analysed by qPCR. 
Primer sequences used for qPCR of SNCA promoter 
genomic regions are listed in Supplementary Table 1.
RNA extraction, reverse transcription-PCR and 
qPCR for gene expression analysis
Total RNA from cells was extracted using High Pure 
RNA Isolation kit (Roche). cDNA was obtained from 1 
μg of RNA using SuperScript ViLO cDNA synthesis 
(Invitrogen) according to manufacturer’s instructions. 
Gene expression was analysed by real-time PCR using 
LightCycler 480 SYBR green I master mix (Roche), 
corrected by GAPDH expression and expressed as 
relative units. Primer sequences used for qPCR assessment 
of SNCA, p27, p21 and control genes are listed in 
Supplementary Table 1.
Protein overexpression and shRNA lentiviral 
infection
HEK-293T and c17.2 cells were infected with pLV-
Ires-GFP plasmid expressing the p27 WT gene. HEK-
293T cells were infected with MISSION shRNA control 
vector and specific p27, p21 or E2F4 shRNAs (Sigma 










The protocol for viral particles production and cell 
infections has been described elsewhere [40]. 24 h after 
infection, cells expressing shRNAs were selected with 2 
mg/ml of Puromycin (Sigma Aldrich) for 5 days. ShRNA-
mediated down-regulation was tested by WB with specific 
antibodies.
CRISPR transfection and clone production
4 μg of control double Nickase plasmid (sc-
437281) or 4 μg of double Nickase plasmid expressing a 
guide RNA sequence targeting a region on p27 gene (sc-
419608-NIC) were used to transfect c17.2 cells. 48 h after 
transfection, GFP-positive cells were sorted using a BD 
FACS Aria Cell Sorting System, selecting one single cell 
per well. 2-3 weeks later, clones were amplified and p27 
expression was analysed by WB.
β-galactosidase and luciferase assays
Luciferase vector was obtained by cloning a 
specific region from the SNCA promoter (-2000 pb) 
into a pGL2 Basic vector. Primers for the selected 
gene were designed by adding MluI and BglII target 
sequences at 5′ and 3′, respectively. The primers used 
for this amplification were: SNCA promoter Forward 
5′ - CTAGAAGGAGAGAAGTCGATAGTG- 3′, SNCA 
promoter Reverse 5′ - GGAGCACATTCCCCCGGA 
TGGAAG- 3′.
Amplification of SNCA promoter sequence was 
made by PCR using genomic DNA and cloning the 
PCR products into a pGL2 vector. HEK-293T cells 
expressing shRNA control, shRNA for p27 or shRNA for 
E2F4 were co-transfected with CMV-βGal vector and a 
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vector containing SNCA promoter. β-galactosidase and 
luciferase assays were performed 48 h after transfection. 
β-galactosidase activity was detected using ONPG 
(Sigma) and read at 405 nm wavelength. Luciferase 
assays (Luciferase Assay System; Promega, Madison, WI) 
were performed following manufacturer’s instructions. 
Luciferase/β-galactosidase ratio was performed and shown 
as arbitrary units (RLU: relative light unit).
Statistical analysis
GraphPad Prism 5.01 (GraphPad Software, San 
Diego, CA, USA) was used for data analysis. The 
Student’s t-test was applied to determine significant 
differences between groups. In these analyses P-values 
of 0.05 were considered to be significant. At least three 
independent samples were analysed in each experiment. 
The significance of the correlation between p27 and p21 
levels was estimated by linear regression analysis using 
the statistical package for the social sciences (SPSS).
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